Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review.

de Ruijter TC, van der Heide F, Smits KM, Aarts MJ, van Engeland M, Heijnen VCG.

Breast Cancer Res. 2020 Jan 31;22(1):13. doi: 10.1186/s13058-020-1250-9.

2.

Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.

Verheijden RJ, May AM, Blank CU, Aarts MJB, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, Boers-Sonderen MJ, van der Hoeven JJM, Hospers GA, Piersma D, van Rijn RS, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van Zeijl MCT, Wouters MWJM, Haanen JBAG, Kapiteijn E, Suijkerbuijk KPM.

Clin Cancer Res. 2020 Jan 27. doi: 10.1158/1078-0432.CCR-19-3322. [Epub ahead of print]

PMID:
31988197
3.

Molecular testing in metastatic basal cell carcinoma.

Verkouteren BJA, Wakkee M, van Geel M, van Doorn R, Winnepenninckx VJ, Korpershoek E, Mooyaart AL, Reyners AKL, Terra JB, Aarts MJB, Reinders MGHC, Mosterd K.

J Am Acad Dermatol. 2019 Dec 21. pii: S0190-9622(19)33303-1. doi: 10.1016/j.jaad.2019.12.026. [Epub ahead of print]

PMID:
31870915
4.

Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?

Schouwenburg MG, Suijkerbuijk KPM, Koornstra RHT, Jochems A, van Zeijl MCT, van den Eertwegh AJM, Haanen JBAG, Aarts MJ, Akkooi ACJV, Berkmortel FWPJVD, Groot JWB, Hospers GAP, Kapiteijn E, Kruit WH, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Hoeven JJMV, Wouters MWJM.

Cancers (Basel). 2019 Dec 4;11(12). pii: E1940. doi: 10.3390/cancers11121940.

5.

Cancer-related cognitive problems at work: experiences of survivors and professionals.

Klaver KM, Duijts SFA, Engelhardt EG, Geusgens CAV, Aarts MJB, Ponds RWHM, van der Beek AJ, Schagen SB.

J Cancer Surviv. 2019 Nov 25. doi: 10.1007/s11764-019-00830-5. [Epub ahead of print]

PMID:
31768861
6.

Platinum exposure and cause-specific mortality among patients with testicular cancer.

Groot HJ, van Leeuwen FE, Lubberts S, Horenblas S, de Wit R, Witjes JA, Groenewegen G, Poortmans PM, Hulshof MCCM, Meijer OWM, de Jong IJ, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJB, Jóźwiak K, van den Belt-Dusebout AW, Gietema JA, Schaapveld M.

Cancer. 2020 Feb 1;126(3):628-639. doi: 10.1002/cncr.32538. Epub 2019 Nov 15.

7.

The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study.

de Ruijter TC, Smits KM, Aarts MJ, van Hellemond IEG, Van Neste L, de Vries B, Peer PGM, Veeck J, van Engeland M, Tjan-Heijnen VCG.

Diagn Progn Res. 2019 Oct 17;3:20. doi: 10.1186/s41512-019-0065-6. eCollection 2019.

8.

Health-Related Quality of Life, Satisfaction with Care, and Cosmetic Results in Relation to Treatment among Patients with Keratinocyte Cancer in the Head and Neck Area: Results from the PROFILES Registry.

Arts LPJ, Waalboer-Spuij R, de Roos KP, Thissen MRTM, Scheijmans LJ, Aarts MJ, Oerlemans S, Lybeert MLM, Louwman MWJ.

Dermatology. 2019 Aug 21:1-10. doi: 10.1159/000502033. [Epub ahead of print]

9.

Diagnostic DNA Methylation Biomarkers for Renal Cell Carcinoma: A Systematic Review.

Lommen K, Vaes N, Aarts MJ, van Roermund JG, Schouten LJ, Oosterwijk E, Melotte V, Tjan-Heijnen VC, van Engeland M, Smits KM.

Eur Urol Oncol. 2019 Aug 9. pii: S2588-9311(19)30114-2. doi: 10.1016/j.euo.2019.07.011. [Epub ahead of print] Review.

10.

Melanoma in older patients: declining gap in survival between younger and older patients with melanoma.

Schuurman MS, Hollestein LM, Bastiaannet E, Posthuma EFM, van Akkooi AJC, Kukutsch NA, Aarts MJB, Wakkee M, Lemmens VEPP, Louwman MWJ.

Acta Oncol. 2020 Jan;59(1):4-12. doi: 10.1080/0284186X.2019.1643914. Epub 2019 Jul 26.

PMID:
31347929
11.

Referral Patterns and Outcome of Patients With Synchronous Brain Metastases From Non-small Cell Lung Cancer Treated With Gamma Knife Radiosurgery in a Third-Line Treatment Centre in The Netherlands - A Retrospective Analysis.

Ten Berge DMHJ, Aarts MJ, Hanssens PEJ, Beute GN, Aerts JGJV, Kloover JS.

Clin Oncol (R Coll Radiol). 2020 Jan;32(1):52-59. doi: 10.1016/j.clon.2019.07.004. Epub 2019 Jul 22.

PMID:
31345622
12.

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.

Jochems A, van der Kooij MK, Fiocco M, Schouwenburg MG, Aarts MJ, van Akkooi AC, van den Berkmortel FWPJ, Blank CU, van den Eertwegh AJM, Franken MG, de Groot JB, Haanen JBAG, Hospers GAP, Koornstra RH, Kruit WHJ, Louwman M, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van Zeijl MCT, van der Hoeven KJM, Kapiteijn E.

Cancers (Basel). 2019 Jul 18;11(7). pii: E1007. doi: 10.3390/cancers11071007.

13.

[Fight against cancer in the Netherlands: current state of affairs].

Siesling S, Visser O, Aarts MJ, Verhoeven RHA, Aben KKH, Dinmohamed AG, van Dijk B, van der Aa M, Louwman M, Lemmens VEPP.

Ned Tijdschr Geneeskd. 2019 Jun 17;163. pii: D4150. Dutch.

PMID:
31283131
14.

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).

De Bruijn RE, Mulders P, Jewett MA, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Wood L, van Melick HE, Aarts MJ, Lattouf JB, Powles T, De Jong IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen JB, Bex A.

Eur Urol. 2019 Oct;76(4):437-440. doi: 10.1016/j.eururo.2019.06.006. Epub 2019 Jun 18.

PMID:
31227307
15.

An actualised population-based study on the use of radiotherapy in breast cancer patients in the Netherlands.

Schreuder K, Middelburg JG, Aarts MJ, Merkus JWS, Poortmans PMP, Jobsen JJ, Siesling S, Struikmans H.

Breast J. 2019 Sep;25(5):942-947. doi: 10.1111/tbj.13376. Epub 2019 Jun 4.

PMID:
31165586
16.

Video-assisted thoracic lobectomy versus stereotactic body radiotherapy for stage I nonsmall cell lung cancer in elderly patients: a propensity matched comparative analysis.

Detillon DDEMA, Aarts MJ, De Jaeger K, Van Eijck CHJ, Veen EJ.

Eur Respir J. 2019 Jun 20;53(6). pii: 1801561. doi: 10.1183/13993003.01561-2018. Print 2019 Jun.

PMID:
30923188
17.

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, Del Pilar Laguna M, Wood L, van Melick HHE, Aarts MJ, Lattouf JB, Powles T, de Jong Md PhD IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J.

JAMA Oncol. 2019 Feb 1;5(2):164-170. doi: 10.1001/jamaoncol.2018.5543. Erratum in: JAMA Oncol. 2019 Feb 1;5(2):271.

18.

Risk of diabetes after para-aortic radiation for testicular cancer.

Groot HJ, Gietema JA, Aleman BMP, Incrocci L, de Wit R, Witjes JA, Groenewegen G, de Brouwer P, Meijer OWM, Hulshof MCCM, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, van den Bergh ACM, Kerst JM, van den Belt-Dusebout AW, Lubberts S, Jóźwiak K, Horenblas S, van Leeuwen FE, Schaapveld M.

Br J Cancer. 2018 Oct;119(7):901-907. doi: 10.1038/s41416-018-0248-x. Epub 2018 Oct 9.

19.

[Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry].

van Zeijl MCT, van den Eertwegh AJM, Wouters MWJM, Jochems A, Schouwenburg MG, Haanen JBAG, Aarts MJ, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Koornstra RH, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van der Hoeven KJM.

Ned Tijdschr Geneeskd. 2018 Jun 15;162. pii: D2420. Dutch.

PMID:
30040270
20.

Changes in treatment patterns and survival in elderly patients with stage I non-small-cell lung cancer with the introduction of stereotactic body radiotherapy and video-assisted thoracic surgery.

Detillon DDEMA, Driessen EJM, Aarts MJ, Janssen-Heijnen MLG, van Eijck CHJ, Veen EJ.

Eur J Cancer. 2018 Sep;101:30-37. doi: 10.1016/j.ejca.2018.06.016. Epub 2018 Jul 14.

PMID:
30014972
21.

Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era.

Groot HJ, Lubberts S, de Wit R, Witjes JA, Kerst JM, de Jong IJ, Groenewegen G, van den Eertwegh AJM, Poortmans PM, Klümpen HJ, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, Incrocci L, van den Bergh ACM, Jóźwiak K, van den Belt-Dusebout AW, Horenblas S, Gietema JA, van Leeuwen FE, Schaapveld M.

J Clin Oncol. 2018 Aug 20;36(24):2504-2513. doi: 10.1200/JCO.2017.77.4174. Epub 2018 Jul 10.

PMID:
29989856
22.

Epigenetics in renal cell cancer: mechanisms and clinical applications.

Joosten SC, Smits KM, Aarts MJ, Melotte V, Koch A, Tjan-Heijnen VC, van Engeland M.

Nat Rev Urol. 2018 Jul;15(7):430-451. doi: 10.1038/s41585-018-0023-z. Review.

PMID:
29867106
23.

Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.

Schouwenburg MG, Jochems A, Leeneman B, Franken MG, van den Eertwegh AJM, Haanen JBAG, van Zeijl MCT, Aarts MJ, van Akkooi ACJ, van den Berkmortel FWPJ, Blokx WAM, de Groot JWB, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van der Hoeven JJM.

Melanoma Res. 2018 Aug;28(4):326-332. doi: 10.1097/CMR.0000000000000453.

PMID:
29750749
24.

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.

Jochems A, Leeneman B, Franken MG, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, Groenewegen G, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, Uyl-de Groot CA, van der Hoeven KJM.

Anticancer Drugs. 2018 Jul;29(6):572-578. doi: 10.1097/CAD.0000000000000629.

PMID:
29659371
25.

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.

Franken MG, Leeneman B, Jochems A, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, van der Hoeven KJM, Hospers GAP, Kapiteijn E, Koornstra R, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van Zeijl M, Haanen JBAG, Uyl-de Groot CA.

Anticancer Drugs. 2018 Jul;29(6):579-588. doi: 10.1097/CAD.0000000000000628.

PMID:
29634490
26.

Patterns of treatment and survival among older patients with stage III non-small cell lung cancer.

Driessen EJM, Schulkes KJG, Dingemans AC, van Loon JGM, Hamaker ME, Aarts MJ, Janssen-Heijnen MLG.

Lung Cancer. 2018 Feb;116:55-61. doi: 10.1016/j.lungcan.2017.12.013. Epub 2017 Dec 20.

PMID:
29413051
27.

Association of socioeconomic status with outcomes in older adult community-dwelling patients after visiting the emergency department: a retrospective cohort study.

Wachelder JJH, van Drunen I, Stassen PM, Brouns SHA, Lambooij SLE, Aarts MJ, Haak HR.

BMJ Open. 2017 Dec 26;7(12):e019318. doi: 10.1136/bmjopen-2017-019318.

28.

Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.

Weberpals J, Jansen L, van Herk-Sukel MPP, Kuiper JG, Aarts MJ, Vissers PAJ, Brenner H.

Eur J Epidemiol. 2017 Nov;32(11):1019-1031. doi: 10.1007/s10654-017-0304-5. Epub 2017 Sep 1.

PMID:
28864947
29.

Neutrophil Recovery in Breast Cancer Patients Receiving Docetaxel-Containing Chemotherapy with and without Granulocyte Colony-Stimulating Factor Prophylaxis.

Aarts MJ, Vriens BE, de Boer M, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Tol J, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, van der Rijt CCD, Smilde TJ, van der Velden AW, Peer N, Tjan-Heijnen VCG.

Oncology. 2017;93(5):323-328. doi: 10.1159/000479067. Epub 2017 Aug 22.

PMID:
28848182
30.

Prognostic DNA methylation markers for renal cell carcinoma: a systematic review.

Joosten SC, Deckers IA, Aarts MJ, Hoeben A, van Roermund JG, Smits KM, Melotte V, van Engeland M, Tjan-Heijnen VC.

Epigenomics. 2017 Sep;9(9):1243-1257. doi: 10.2217/epi-2017-0040. Epub 2017 Aug 14. Review.

31.

Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer.

Vriens BEPJ, Vriens IJH, Aarts MJB, van Gastel SM, van den Berkmortel FWPJ, Smilde TJ, van Warmerdam LJC, van Spronsen DJ, Peer PGM, de Boer M, Tjan-Heijnen VCG; Breast Cancer Trialists’ Group of the Netherlands (BOOG).

Breast Cancer Res Treat. 2017 Oct;165(3):593-600. doi: 10.1007/s10549-017-4364-8. Epub 2017 Jul 3.

32.

Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990-2014): Disparities between younger and older patients.

Driessen EJ, Aarts MJ, Bootsma GP, van Loon JG, Janssen-Heijnen ML.

Lung Cancer. 2017 Jun;108:198-204. doi: 10.1016/j.lungcan.2017.04.005. Epub 2017 Apr 10.

PMID:
28625635
33.

Timed Get Up and Go Test and Geriatric 8 Scores and the Association With (Chemo-)Radiation Therapy Noncompliance and Acute Toxicity in Elderly Cancer Patients.

Middelburg JG, Mast ME, de Kroon M, Jobsen JJ, Rozema T, Maas H, Baartman EA, Geijsen D, van der Leest AH, van den Bongard DJ, van Loon J, Budiharto T, Coebergh JW, Aarts MJ, Struikmans H; LPRO (Dutch National Organization for Radiotherapy in the Elderly).

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):843-849. doi: 10.1016/j.ijrobp.2017.01.211. Epub 2017 Jan 29.

PMID:
28366575
34.

Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies.

Vriens BEPJ, Keymeulen KBMI, Kroep JR, Charehbili A, Peer PG, de Boer M, Aarts MJB, Heuts EM, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG).

Oncotarget. 2017 Jul 11;8(28):46557-46564. doi: 10.18632/oncotarget.15101.

35.

The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients.

Vriens IJ, De Bie AJ, Aarts MJ, de Boer M, van Hellemond IE, Roijen JH, van Golde RJ, Voogd AC, Tjan-Heijnen VC.

Oncotarget. 2017 Feb 14;8(7):11372-11379. doi: 10.18632/oncotarget.14532.

36.

Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.

Jochems A, Schouwenburg MG, Leeneman B, Franken MG, van den Eertwegh AJ, Haanen JB, Gelderblom H, Uyl-de Groot CA, Aarts MJ, van den Berkmortel FW, Blokx WA, Cardous-Ubbink MC, Groenewegen G, de Groot JW, Hospers GA, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MW, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MW, van der Hoeven JJ.

Eur J Cancer. 2017 Feb;72:156-165. doi: 10.1016/j.ejca.2016.11.021. Epub 2016 Dec 25.

PMID:
28030784
37.

[Vismodegib for basal cell carcinoma: targeted therapy in case of locally advanced or metastasised disease].

Reinders MG, Terra JB, Reyners AK, Aarts MJ, de Haas ER, Mosterd K.

Ned Tijdschr Geneeskd. 2016;160:D187. Dutch.

PMID:
28000572
38.

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.

Cirkel GA, Hamberg P, Sleijfer S, Loosveld OJL, Dercksen MW, Los M, Polee MB, van den Berkmortel F, Aarts MJ, Beerepoot LV, Groenewegen G, Lolkema MP, Tascilar M, Portielje JEA, Peters FPJ, Klümpen HJ, van der Noort V, Haanen JBAG, Voest EE; Dutch WIN-O Consortium.

JAMA Oncol. 2017 Apr 1;3(4):501-508. doi: 10.1001/jamaoncol.2016.5202.

PMID:
27918762
39.

A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients.

van Vlodrop IJH, Joosten SC, De Meyer T, Smits KM, Van Neste L, Melotte V, Baldewijns MMLL, Schouten LJ, van den Brandt PA, Jeschke J, Yi JM, Schuebel KE, Ahuja N, Herman JG, Aarts MJ, Bosman FT, Van Criekinge W, van Engeland M.

Clin Cancer Res. 2017 Apr 15;23(8):2006-2018. doi: 10.1158/1078-0432.CCR-16-1236. Epub 2016 Oct 18.

40.

Promoter CpG island methylation in ion transport mechanisms and associated dietary intakes jointly influence the risk of clear-cell renal cell cancer.

Deckers IA, van Engeland M, van den Brandt PA, Van Neste L, Soetekouw PM, Aarts MJ, Baldewijns MM, Keszei AP, Schouten LJ.

Int J Epidemiol. 2017 Apr 1;46(2):622-631. doi: 10.1093/ije/dyw266.

PMID:
27789672
41.

Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands.

Blommestein HM, de Groot S, Aarts MJ, Vemer P, de Vries R, van Abeelen AF, Posthuma EF, Uyl-de Groot CA.

Leuk Res. 2016 Nov;50:37-45. doi: 10.1016/j.leukres.2016.09.005. Epub 2016 Sep 3.

42.

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.

Badrising SK, van der Noort V, Hamberg P, Coenen JL, Aarts MJ, van Oort IM, van den Eertwegh AJ, Los M, van den Berg HP, Gelderblom H, Vrijaldenhoven S, Kerver ED, van Voorthuizen T, de Jong IJ, Haanen JB, Bergman AM; Dutch Uro-Oncology Study Group (DUOS).

Oncology. 2016;91(5):267-273. Epub 2016 Aug 20.

PMID:
27544669
43.

Sunitinib uptake inhibits platelet function in cancer patients.

Sabrkhany S, Griffioen AW, Pineda S, Sanders L, Mattheij N, van Geffen JP, Aarts MJ, Heemskerk JW, Oude Egbrink MG, Kuijpers MJ.

Eur J Cancer. 2016 Oct;66:47-54. doi: 10.1016/j.ejca.2016.07.016. Epub 2016 Aug 12.

PMID:
27525572
44.

The beneficial local and abscopal effect of splenic irradiation in frail patients with chronic lymphocytic leukaemia.

Aalbers AM, Aarts MJ, Krol AD, Marijnen CA, Posthuma EF.

Neth J Med. 2016 Mar;74(3):122-9.

45.

Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer.

Vriens BE, de Vries B, Lobbes MB, van Gastel SM, van den Berkmortel FW, Smilde TJ, van Warmerdam LJ, de Boer M, van Spronsen DJ, Smidt ML, Peer PG, Aarts MJ, Tjan-Heijnen VC; INTENS Study Group.

Eur J Cancer. 2016 Jan;52:67-76. doi: 10.1016/j.ejca.2015.10.010. Epub 2015 Nov 30.

PMID:
26650831
46.

Presence and Number of Positive Surgical Margins after Radical Prostatectomy for Prostate Cancer: Effect on Oncological Outcome in a Population-Based Cohort.

Richters A, Derks J, Fossion LM, Kil PJ, Verhoeven RH, Aarts MJ.

Urol Int. 2015;95(4):472-7. doi: 10.1159/000441012. Epub 2015 Nov 3.

PMID:
26523366
47.

A qualitative study on the views of experts regarding the incorporation of non-health outcomes into the economic evaluations of public health interventions.

van Mastrigt GA, Paulus AT, Aarts MJ, Evers SM, Alayli-Goebbels AF.

BMC Public Health. 2015 Sep 24;15:954. doi: 10.1186/s12889-015-2247-7.

48.

Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.

Badrising SK, van der Noort V, van den Eertwegh AJ, Hamberg P, van Oort IM, van den Berg HP, Los M, Aarts MJ, Coenen JL, Gelderblom H, de Jong IJ, Kerver ED, Vrijaldenhoven S, van Voorthuizen T, Warmerdam F, Haanen JB, Bergman AM; Dutch Uro-Oncology Studygroup.

Prostate. 2016 Jan;76(1):32-40. doi: 10.1002/pros.23094. Epub 2015 Sep 22.

PMID:
26390914
49.

Variation in circumferential resection margin: Reporting and involvement in the South-Netherlands.

Homan J, Bökkerink GM, Aarts MJ, Lemmens VE, van Lijnschoten G, Rutten HJ, Wijsman JH, Nagtegaal ID, de Wilt JH.

Eur J Surg Oncol. 2015 Nov;41(11):1485-92. doi: 10.1016/j.ejso.2015.07.015. Epub 2015 Jul 29.

PMID:
26251342
50.

Exploring Outcomes to Consider in Economic Evaluations of Health Promotion Programs: What Broader Non-Health Outcomes Matter Most?

Benning TM, Alayli-Goebbels AF, Aarts MJ, Stolk E, de Wit GA, Prenger R, Braakman-Jansen LM, Evers SM.

BMC Health Serv Res. 2015 Jul 14;15:266. doi: 10.1186/s12913-015-0908-y.

Supplemental Content

Loading ...
Support Center